NASDAQ: RAPP - Rapport Therapeutics, Inc.

Altı ay boyunca karlılık: -50.93%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Rapport Therapeutics, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

daha fazla ayrıntı
The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2024-06-07
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.rapportrx.com
Цена ао 9.7
Günlük fiyat değişimi: +3.61% (9.7)
Haftalık fiyat değişimi: +3.4% (9.72)
Aylık fiyat değişimi: -8.97% (11.04)
3 ayda fiyat değişimi: -47.19% (19.03)
Altı ayda fiyat değişimi: -50.93% (20.48)
Yılbaşından bu yana fiyat değişimi: -47.19% (19.03)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 12.05 1
P/E 0 0
EV/EBITDA -43.63 0
Toplam: 0.625

Yeterlik

İsim Anlam Seviye
ROA, % -33.3 0
ROE, % -35.09 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0178 10
Toplam: 9.8

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 0 0
karlılık Ebitda, % 702.31 10
karlılık EPS, % 29.66 4
Toplam: 6.8
Daha fazla ayrıntı

ETFPaylaşmak, %Yıllık karlılık, %Temettüler, %
iShares Neuroscience and Healthcare ETF 0.71137 19.72 0.03
iShares Micro-Cap ETF 0.04983 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00794 38.04 0.6026
0.2624.950.72



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Steven M. Paul M.D. Founder & Independent Chairman 1951 (74 yıl)
Mr. Abraham N. Ceesay M.B.A. CEO, President, Treasurer & Director 1978 (47 yıllar)
Dr. Troy A. Ignelzi Chief Financial Officer 1968 (57 yıllar)
Ms. Cheryl Gault Chief Operating Officer 1979 (46 yıllar)
Mr. David Bredt M.D., Ph.D. Founder & Chief Scientific Officer 1965 (60 yıllar)
Ms. Karina Chmielewski Chief Information Officer & Head of Operations
Ms. Julie DiCarlo Head of Communications & Investor Relations
Ms. Kathleen A. Wilkinson Chief People Officer 1972 (53 yıl)
Dr. Bradley S. Galer M.D. Chief Medical Officer 1962 (63 yıl)
Mr. Swamy Yeleswaram Ph.D. Chief Development Officer 1963 (62 yıl)

Adres: United States, Boston, 1325 Boylston Street - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.rapportrx.com